Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, Chenguang; Wang, Zhaoqin; Zhao, Fang; Yang, Yang; Li, Jinxiu; Yuan, Jing; Wang, Fuxiang; Li, Delin; Yang, Minghui; Li, Xing; Wei, Jinli; Xiao, Haixia; Yang, Yan; Qu, Jiuxin; Qing, Ling; Chen, Li; Xu, Zhixiang; Peng, Ling; Li, Yanjie; Zheng, Haixia; Chen, Feng; Huang, Kun; Jiang, Yujing; Liu, Dongjing; Zhang, Zheng; Liu, Yingxia; Liu, Lei

doi:10.1001/jama.2020.4783

Cited by 2,218 publications

(2,481 citation statements)

References 21 publications

Supporting

Mentioning

2,284

Contrasting

Unclassified

Order By: Relevance

“…patients with ARDS, all had clinical improvement with 3/5 patients weaning from the ventilator (142). Additional trials are ongoing to better define the safety and efficacy of this strategy.…”

Section: Neutralizing Antibodies and Decoy Proteinsmentioning

confidence: 99%

COVID-19 for the Cardiologist

Atri

Siddiqi

Lang

et al. 2020

JACC: Basic to Translational Science

268

137

View full text Add to dashboard Cite

Highlights-Severe acute respiratory virus-2 (SARS-CoV2), the infection responsible for coronavirus disease-2019 (COVID-19), has spread globally leading to a devastating loss of life. In a few short months, the clinical and scientific communities have rallied to rapidly evolve our understanding of the mechanism(s) of disease and potential therapeutics. -This review discusses the current understanding of the basis virology of SARS-CoV2 and the epidemiology, clinical manifestations, including cardiovascular, and mortality of COVID-19. A detailed review of the viral life cycle and putative mechanism(s) of injury frames the discussion of possible preventative and therapeutic strategies. -The ongoing, unprecedented collective effort will, without a doubt, advance our ability to prevent the spread and optimally care for patients suffering from COVID-19. SummaryThe coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), has reached pandemic status. As it spreads across the world, it has overwhelmed healthcare systems, strangled the global economy and led to a devastating loss of life. Widespread efforts from regulators, clinicians and scientists are driving a rapid expansion of knowledge of the SARS-CoV2 virus and the COVID-19 disease.We review the most current data with a focus on our basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. We discuss the basic virology, epidemiology, clinical manifestation, multi-organ consequences, and outcomes. With a focus on cardiovascular complications, we propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies.

show abstract

Section: Neutralizing Antibodies and Decoy Proteinsmentioning

confidence: 99%

COVID-19 for the Cardiologist

Atri

Siddiqi

Lang

et al. 2020

JACC: Basic to Translational Science

268

137

View full text Add to dashboard Cite

show abstract

“…8,9 In addition, many patients have received off-label or compassionate-use therapies, including antiretrovirals, antiparasitic agents, antiinflammatory compounds, and convalescent plasma. [10][11][12][13] Remdesivir is a prodrug of a nucleotide analogue that is intracellularly metabolized to an analogue of adenosine triphosphate that inhibits viral RNA polymerases. Remdesivir has broadspectrum activity against members of several virus families, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]) and has shown prophylactic and therapeutic efficacy in nonclinical models of these coronaviruses.…”

mentioning

confidence: 99%

Compassionate Use of Remdesivir for Patients with Severe Covid-19

et al. 2020

View full text Add to dashboard Cite

“…After getting approval from the ethical committee, Shenzhen, Third People's Hospital, they administrated convalescent plasma containing neutralizing antibodies to 5 critically ill patients with SARS-CoV-2. Among those 3 patients discharged from the hospital and 2 patients under an incubation period of 37 days [23]. Casadevall and Pirofski highlighted the risks of passive administration of convalescent sera, which falls into two categories, serum disease and antibody-dependent enhancement of infection.…”

Section: Convalescent Plasma Therapymentioning

confidence: 99%

A short review on antibody therapy for COVID-19

Kumar

Jeyanthi²,

Ramakrishnan

2020

New Microbes and New Infections

View full text Add to dashboard Cite

The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak . By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.

show abstract

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Cited by 2,218 publications

References 21 publications

COVID-19 for the Cardiologist

COVID-19 for the Cardiologist

Compassionate Use of Remdesivir for Patients with Severe Covid-19

A short review on antibody therapy for COVID-19

Contact Info

Product

Resources

About